



Cutaneous malignant melanoma (CMM) is uncommon in the 
skin of color individuals (SCIs), making documented studies 
in this population few and mostly outdated. In a study of 
incidence rate covering 67.2% of the US population between 
1996 and 2006 in people aged 15–39 from 38 cancer registers, 
a rate of < 1% was recorded in SCIs.[1] Most of the studies on 
the pathogenesis, clinical features, histology, and interventions 
in CMM have been in Caucasians.[2]
The low incidence rate of CMM in SCI has been attributed 
to the constitutive pigmentation of the skin.[3] Following a 
study of 3500 women from different geographic areas, DNA 
damage of melanocytes was found to be dependent on skin 
color with decreased DNA damage in dark skin.[3] The low 
incidence of CMM in SCI makes reviews and comparison of 
studies difficult as most sample sizes are small and studies are 
few. Melanoma‑specific survival (MSS) rates differ between 
ethnic groups, with SCI having lower 5-year survival rates 
than Caucasians even after treatment.[2]
Delayed and advanced presentation in SCI with melanoma 
and its consequent poor prognosis is attributed to a low 
perception of risk of melanoma, low awareness of its risk 
factors and its clinical presentation.[4-7] Available literature 
from different countries of the world shows various prevalence 
rates of malignant melanoma. Also, other features including 
the age of onset, area of onset, anatomic sites affected, clinical 
classification, histopathology, the severity of the disease, 
disease progression and associated diseases are all well 
documented, especially in Caucasians.
Differences in clinical presentation, disease progression, 
and management options in different ethnic groups have 
also been documented; however, this is not the case in SCIs. 
There is little documented knowledge of genetics, clinical and 
histological differences between melanoma in SCI and other 
skin types. Increased knowledge of the difference in clinical 
and histological characteristics between melanoma on the skin 
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of SCI and other skin types would improve patient management 
by being able to provide accurate information to patients and 
their families and thus contribute to better survival.
The aim of this review is to document the clinical, genetic, 
histopathological characteristics, and variants of melanoma 
in SCI. Also, to highlight differences between melanoma in 
SCI and Caucasians.
MaterIals and Methods
Four electronic databases (PubMed, Google Scholar, Ovid, 
and Embase) were systematically searched to find articles 
published on CMM using the following search words; 
cutaneous melanoma, blacks, whites, Caucasians, skin of 
colour, ethnic skin, African Americans, nonwhites, differences 
and comparison between ethnic groups. In addition, the 
reference lists of selected articles were checked for additional 
relevant articles.
SCIs in this study refers to all groups with dark skin of African 
descent (African Americans, Africans, Africans with mixed 
ancestry).[8] One hundred and seventy-three papers were 
reviewed, with sixty‑six specifically addressing cutaneous 
melanoma in people of SCI. Papers of studies specifically 
conducted in SCI and papers specifically addressing 
differences in SCI and Caucasians were reviewed. Fifty-eight 
papers dated from the year 2000 to date were finally chosen for 
review. Older manuscripts were excluded as they either did not 
contain information different from those in the selected papers 
or did not address the study aims. Data were entered into SPSS 
version 18. Simple frequencies are presented.
epIdeMIology of cutaneous MelanoMa
Epidemiological studies have documented the occurrence of 
CMM in SCI, although the incidence is low compared to that 
of Caucasians and other ethnic groups.[2] The incidence rate 
of CMM varies between 21.6 and 50 per 100,000 persons per 
year in Caucasians and 1.0–1.2 per 100,000 persons per year 
in SCI.[9] Age-adjusted incidence rates per 100,000 persons per 
year in men and women vary between ethnic groups.[10] This 
varies between 9.55 and 17.2 in Caucasian males, 7.88 and 
11.3 in Caucasian females to 0.69 and 1.2 in SCI males and 
0.7 in SCI females.[10] A 1.5 fold increase in the incidence of 
CMM in Caucasians from 18.2 in 1992 to 26.3 in 2004 was 
noted, and for the same period, a 1.6 fold increase in incidence 
in SCI from 0.5 to 0.8[10] Incidence data of CMM extracted 
from Surveillance, Epidemiology and End Results (SEER) 
covering different time periods revealed that SCI accounted 
for 0.4%–1.0% of CMM while Caucasians accounted for 
95%–99%.[2,5,11]
Epidemiological studies of cancers in Africa revealed that 
melanoma made up 31% of cancers in Cotonou,[12] 9.9% 
in Nigeria.[13] In Togo, no single case of melanoma was 
diagnosed from 1984 to 2008.[14] Evaluation of time trends 
in melanoma incidence in SCI shows conflicting results. 
Some reports show no change in incidence,[4,5] while another 
report showed a 1.6 fold increase in melanoma from 0.5 to 
0.8/100,000 persons/year.[10] The reason for this difference in 
reports may be due to the fact that these data were extracted 
from different geographical locations in the US though it was 
done in the same period.
The average age at diagnosis of melanoma in SCI varies 
between 56 and 60 years, although, most people are 
diagnosed between age 50 and 64 years.[5,11] Acral lentiginous 
melanoma (ALM), the most prevalent type of CMM in 
SCI is diagnosed mainly a decade later in the age range of 
60–70 years.[15] Data from SEER show that SCI is diagnosed 
at a slightly older age than Caucasians, with an average of 59 
and 55 years, respectively.[16]
Differences exist in the characteristics of CMM between males 
and females of SCI. More males than females are diagnosed 
with CMM. Most studies show male-to-female (M: F) ratios 
of between 1–1.7:0.6–1.3.[2,13,17] Though Ultraviolet B radiation 
(UVB) is not thought to be a major risk factor for melanoma in 
SCI, it was found following a study of the association of UVB 
with melanoma in SCI that, in males, there was an increased 
risk of death for a 50% increase in UVB radiation. No such 
increase was observed in females.[11]
rIsk factors for MelanoMa In skIn of colour 
IndIvIduals
Melanoma development in an individual is dependent on 
the individual’s phenotype, genotype, and environmental 
factors.[18] The risk factors of CMM in SCI is not as well 
known as that in Caucasians in whom extensive studies have 
been done, and the risk factors are well known.[18,19] Ultraviolet 
radiation is not thought to be a major risk factor for melanoma 
in SCI. A study comparing ultraviolet (UV)-induced DNA 
damage in people of different ethnicity showed that all skin 
types experience DNA damage following UV exposure.[20] This 
study also showed that the SCI skin recovers over hours with 
little or no residual DNA damage one week after ultraviolet 
radiation (UVR) exposure.[20] This is unlike what happens with 
Caucasian skin, which takes days to recover and has residual 
DNA damage one week after UVR exposure.[20]
The skin of SCI has a high melanin content, and this is 
protective against the development of melanoma in this group 
of people. Following a study of 3500 women of African descent 
DNA damage was higher the lighter, the skin phenotype.[3] 
SCIs may require high environmental exposure to sunlight 
to induce CMM.
Trauma as a risk factor for melanoma has also been evaluated 
and was not found to be an aetiological factor in SCI.[21,22] It 
is thought that, if the trauma had been an aetiological factor 
for melanoma, the rate of subungual melanoma would have 
been higher than it is now as the hand is commonly subject 
to trauma. Other reported risk factors for melanoma in SCI 
include albinism, radiation therapy, immunosuppression, burn 
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scars, pre-existing nevus (especially acral), and congenital 
naevus.[22,23]
In summary, the risk factors for melanoma in SCI are still 
uncertain with conflicting reports from various studies. This 
review raises the hypothesis that melanoma in SCI may have 
a different histogenesis from melanoma in Caucasians.
clInIcal features
Cutaneous melanoma in SCI presents as a dark macule or patch 
with a gradual increase in size commonly on the plantar and 
palmar aspects of limbs, unlike what is observed in Caucasians 
in whom melanoma is commonly truncal [Figure 1].[19,24,25] 
Subungual melanomas present as a pigmented band wider 
than 3 mm on the nail with Hutchinson’s sign. They exhibit 
pigment variation, rapid growth in size, and these lesions are 
usually solitary[19] [Figure 2].
The anatomical distribution of melanoma differs between 
SCI and Caucasians. SCIs tend to have melanomas in nonsun 
exposed areas, unlike Caucasians who have melanomas in 
sun-exposed areas. In SCI, 79%–93.7% of lesions are acral.[13] 
A comparison of the percentage anatomical distribution of 
melanomas between SCI and Caucasians is shown in 
Table 1.[2,5] Differences also exist in the site of melanoma 
presentation between genders both within and inter-ethnic 
groups [Table 1]. Caucasian men seem to have most of their 
melanomas on the trunk while Caucasian women have most 
of their melanomas on their lower limbs. Amongst SCI, 
melanomas are mainly on the lower legs, but women appear 
to rarely have melanomas anywhere else unlike the men who 
have melanomas in other body sites. It is not known why this 
difference in the determiner distribution of melanomas occurs.
MIsdIagnosIs
Melanomas in SCI are commonly misdiagnosed as other 
pigmented skin lesions mainly because of the pigmentation. 
Melanomas may be misdiagnosed as fungal infections, 
subungual hematoma, tinea nigra, pigmented basal cell 
carcinoma, tinea corporis, tinea mannum, talon noir, erythema 
dyschromicum perstans, fixed drug eruption, melasma, 
localized argyria, exogenous ochronosis, melanotic lupus 
erythematosus, Berloque dermatitis, and pigmented viral 
warts.[19,26,27]
delay In presentatIon
SCIs tend to present late, with delays of up to 5.6 years 
before diagnosis.[15] Most of these patients present because 
of bleeding and enlargement of a pigmented skin lesion.[15] 
Postulated reasons for the delay in presentation include a 
misconception of never getting melanoma, poor accessibility 
of health care, lesions in unusual sites (plantar, subungual). 
Specifically, people with plantar melanoma present late with 
a mean duration of 3.1 years.[12]
MSS is lower in SCI than in Caucasians. The 5-year survival 
for thin melanomas is lower in SCI than in Caucasians, but 
they have almost the same survival in advanced melanomas.[2] 
Zell et al. documented a 5- and 10-year survival of 79.8% and 
64.4% respectively in Caucasians compared to 63.2% and 
44.9% in SCI.[28]
survIval
In a study of ALM, the 5- and 10-year MSS in SCI was 77.2% 
and 69.4%, respectively compared to 82.6% and 71.5% in 
Caucasians.[29] ALM results in a higher mortality in SCI 
mainly because of thicker tumors and late-stage presentation. 
However, when Breslow thickness (BT) is > 2.0 mm, there 
is no observed difference in survival between Caucasians and 
SCI.[29] Survival with ALM is poorer than in other cutaneous 
melanomas (CMM); CMM is associated with 5 and 10-year 
survival of 91.3% and 87.3% compared to 80.3% and 67.5%, 
respectively, in ALM.[29]
Furthermore, survival following surgery is low in SCI.[16] 
The 10 years MSS was 73% compared to 88% in Caucasians 
irrespective of the type of surgery.[16] This low survival is 
due to SCI presenting more with advanced melanomas. 
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Survival in SCI is also stage dependent. Stage 1 disease had 
52.68% and 11.07%, 5- and 10-year survival, respectively.[30] 
When compared to Caucasians; survival from Stage 1 CMM 
is 75.97% in Caucasians and 52.68% in SCI and survival 
from local disease occur in 58.8% of Caucasians and 43% 
of SCI.[16,30] Survival is also dependent on the site of melanoma, 
with acral melanoma being associated with a low survival rate 
compared to truncal melanoma.[30]
treatMent
Caucasians and SCI are offered the same modalities 
of treatment (surgery, radiotherapy, immunotherapy, 
chemotherapy). However, amputation occurs more commonly 
in SCI.[28] Amputation is carried out in 10.5% of SCI compared 
to 0.3% of Caucasians mainly because of the presentation 
of ALM in people of African descent.[28] Due to late-stage 
presentation, only 71.7% of SCI have surgery compared to 
83.4% of Caucasians[16] [Table 2].
prognosIs
Melanomas in SCI carry a poor prognosis in contrast to what 
is observed in Caucasians, although for the advanced stage at 
diagnosis, there is no difference in prognosis[16,31] [Table 2]. Factors 
responsible for poor prognosis are; advanced stage lesions, delayed 
presentation, ulceration of lesions, site of melanoma, and type of 
melanoma.[31-33] Subungual melanoma, acral lesions, increased BT, 
and histological subtype of ALM convey a poor prognosis.[29,31,34] 
These melanomas present with increased tumor thickness, which 
is one of the prognostic signs for melanoma.[29,31,32]
MelanoMa stagIng
When it comes to staging of melanoma, SCI from various 
studies are more likely to present with 19%–55% Stage 3 and 
Stage 4 melanoma with only 11%–37% presenting with Stage 1 
and Stage 2 melanomas.[4,5] This advanced stage presentation 
in SCI has been attributed to many factors, including the site 
of melanoma lesions, the atypical features of melanoma in 
SCI, and the perceived low risk of melanoma.[6,25] Conclusions 
drawn from data on ALM from 17 Cancer Registries covering 
26% of the US population is that ALM, the main presentation 
in SCI is associated with an advanced stage at presentation, 
with increased tumor thickness and confers a poor prognosis.[29]
cost
The cost of treating melanoma is high.[35] The average cost 
of year per potential life lost in an SCI due to melanoma is 
$413,913 in the United States of America (USA).[36] Patients 
on Medicaid tend to present later than people who can afford 
private insurance, and a low socioeconomic status leads to 
presentation with advanced lesions.[35]
awareness and perceptIon of rIsk of MelanoMa
The level of perception of the risk of melanoma in SCI is 
low.[6,37] SCIs view their risk of melanoma to be low and 
they also have a low awareness of the typical features of 
melanoma.[7,38,39] Pain is thought to be the sign of melanoma 
and they also have inaccurate beliefs about melanoma and do 
not think that it is associated with their lifestyle.[38]
There is a misconception of cutaneous melanoma in SCI 
both by patients and doctors.[40] Only 17% of SCI compared 
to 61% of Caucasians see the doctor for a complete skin 
examination.[7] Total body skin examination in SCI both by 
patients and dermatologists is low due to a low perception 
of risk of melanoma in SCI.[7] No advice on sun protection is 
given to SCI group of patients. Educating SCI about the clinical 
features of melanoma and risk of melanoma will lead to early 
diagnosis and improved survival in this group of people.
preventIon practIces
Sun protection practice is low in SCI. SCIs were found to 
be less likely to use sunscreen compared to Caucasians in a 
study of sunscreen use.[41] A study of sun protection practices 
Table 2: Comparison of cutaneous melanoma between 
skin of colour individuals and Caucasians




Lower limbs and hips 39–81 19
Trunk 6–19.7 31–34
Head and neck 5.1–11.9 19.4
Upper limbs and shoulders 10.7–12.9 24
Treatment
Rate of amputations 10.5 0.3
Rate of surgery 71.7 83.4
Disease stage presentation
Local disease 65.1–69 80
Regional and distant 
metastasis
24.5–52 10.1–16
Early stage presentation 
incidence/100,000
23.6 0.7




Sun screen 15.4 30.1
Wide bream hat 29.3 20.7
Sun glasses 47.1 62.9
Table 1: Distribution frequency of melanomas between 
genders in skin of colour individuals and caucasians
Site Skin of colour 
individuals (%)
Caucasians (%)
Males Females Males Females
Head and neck 12 2 22 13
Trunk 14 7 40 23
Upper limbs 14 2 21 25
Lower limbs 50 63 9 32
Unknown 10 26 9 6
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amongst postal workers revealed the following practices; 
only 15.4% of SCI compared to 30.1% whites use sunscreen, 
29.3% of SCI compared to 20.7% of Caucasians use wide brim 
hats, and only 47% SCI compared to 62.9% of Caucasians 
use sunglasses.[41] In another study of 50 dermatologists, sun 
protection counseling was not routinely given to SCI despite 
the thinking that sun protection is important in SCI.[42]
Educating SCI about the clinical features of melanoma and 
their risk of melanoma will lead to protective behavior, 
prevention, and early diagnosis of melanomas.[32,39] Careful 
examination of the acral site should be advised in SCI as 
most of the melanomas in this group is acral.[33] Public health 
education on the risk of melanoma, screening for recurrences 
should be advocated in SCI. Regular skin self-examinations 
and doctor examinations should be performed in SCI with 
advice on sun protection habits.[19]
hIstogenesIs of MelanoMa
Currently, there are no documented differences in the 
histopathology of cutaneous melanoma between SCI and 
other ethnic groups. The same histological features are 
observed. However, the differing subtypes, aetiological 
factors, and anatomic site of occurrence have raised questions 
about differences in melanoma genesis between these two 
populations.
hIstologIcal characterIstIcs
Studies on the histological type of melanomas in SCI reveal 
ALM to be the most predominant subtype.[2,5,16] This is in 
contrast to what is seen in Caucasians who predominantly 
present with superficial spreading melanoma (SSM).[5,16] The 
prevalence of the histological subtypes of melanoma in African 
skin is shown[2,5,16,28,34] in Table 3.
ALM is the most prevalent melanoma in SCI, followed 
by SSM, nodular melanoma (NM), and lentigo maligna 
melanoma (LMM). The least frequent subtypes of melanoma 
in SCI are desmoplastic and amelanotic melanoma.[2,5,24,34]
Also the proportions of the different subtypes of melanoma 
have been observed to differ by gender in SCI[43] [Table 4]. 
Thus in SCI, men present more with ALM while females 
present more with SSM. The reason for this difference is not 
known. On the other hand, in Caucasians, there is no difference 
between men and women in the subtypes of melanoma as the 
most prevalent subtype in both genders is SSM.
Breslow thIckness
The reported BT is more in SCI, being 1.2–1.3 mm compared 
to 0.66–0.8 mm in Caucasians.[41] Thirty‑two to fifty percent 
of SCI present with a BT of > 3 mm and only 12% with a BT 
of < 1–0 mm.[44] A BT of > 6.5 mm has been recorded in SCI.[38] 
BT in ALM is thicker than in other histological subtypes of 
melanoma.[24]
ulceratIon
Ulcerated lesions are frequently seen in 10.4%–59% of 
SCI.[5,16,28] This is in contrast to Caucasians in whom only 
4.4%–5.0% present with ulcerated lesions.[5,16,28] Ulcerated 
lesions confer a poor prognosis as patients with ulcerated 
lesions have < 31 months survival compared to 86 months 
people with no ulceration.[6] As previously stated, SCI with 
ulcerated lesions tend to present more with advanced disease; 
48% present with Stage 3 and Stage 4 disease, while only 11% 
present with Stage 1 and Stage 2 disease.[6]
classIfIcatIon of MelanoMas
There are four main classifications of melanoma based on the 
anatomical site of origin and intraepidermal growth pattern. 
The four subtypes are; ALM, SSM, LMM, and NM. In SCIs, 
the most common subtype of melanoma is ALM followed by 
SSM, the NM and least of all LMM.[2,5,16,24,28,34]
ALM is the most prevalent subtype of melanoma in SCI 
and it occurs mostly on the sole of the foot, one of the least 
sun-exposed areas of the body.[2,24] SSM is the second most 
common subtype of melanoma in SCI and it occurs more in 
women.[5] NM, the third most common melanoma in SCI, 
occurs more in men than women.[5,45,46] LMM is the least 
common melanoma in SCI.[2,14] This is most probably due 
to melanin protection from UVR of the skin in this group of 
people as LMM occurs on sun-damaged skin, especially of 
the face.[47]
genetIcs of MelanoMa
Melanomas arise from different molecular pathways with 
the different subtypes of melanoma associated with different 
genetic mutations.[47,48] The molecular pathways that have been 
Table 3: Comparison of melanoma subtypes between skin 
of colour individuals and Caucasians




Acral lentiginous melanoma 10.4–66 0.4–2
Superficial spreading melanoma 4–23 18–26.5
Nodular melanoma 0.8–22.5 6.8–5
Lentigo maligna melanoma 2.4–8.9 3.7–13.8
Amelanotic melanoma 0.0–0.8 0.4–0.5
Desmoplastic melanoma 0.85–1.4 0.4–2.2
Table 4: Comparison of subtypes of melanoma between 
males and females skin of colour individuals
Subtype of melanoma Males (%) Females (%)
Acral lentiginous melanoma 12.1–19 13.7–16
Nodular melanoma 4.7–10 6–9
Superficial spreading melanoma 7–16.1 22
Lentigo maligna melanoma 2–4.7 0–5.1
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reported in CMM are Cyclin D1, Neuroblastoma RAS (NRAS), 
and BRAF, Cyclin-dependent kinase inhibitor 2A (CDKN2A), 
Melanocortin 1 receptor (MC1R), and Kit-ligand (C-kit).[48-51]
Several studies have been conducted on the genetics of CMM 
in Caucasians but not many specifically with SCI.[52] This is due 
to the low incidence of melanoma in this group of people and 
consequently, too few people for the study. SCIs have a low 
incidence of gene mutation, further enhancing the theory that 
melanoma in SCI has different pathogenesis from melanoma 
in Caucasians.[52] Given that the risk factors for and subtypes 
of melanoma in SCI are different from those in Caucasians, 
genetic mutations may also differ.
Cyclin D1 amplification occurs early and is said to play a role 
in the genesis of cutaneous melanoma, especially in ALM 
compared to other melanomas and this is independent of the 
presence or absence of p16 mutation.[49] Another gene mutation 
associated with ALM is c-kit.[50] Kit mutation is found mainly 
in metastatic acral and mucosal melanomas.[50] Kit-ligand is a 
stem cell factor required by melanocytes for development and 
maintenance. Loss of kit expression is associated with high 
metastatic potential.[50]
NRAS and BRAF mutations occur early in melanocytic 
lesions as these mutations are found in naevi.[48] This mutation 
is associated with melanomas on nonchronic sun-damaged 
skin.[53] Thus mutations of BRAF and NRAS are found to be 
low in ALM the commonest melanoma in SCI which is not 
associated with sun exposure. Thus BRAF mutation is not 
expected to be high and may not found in SCI.
In a study of 26 SCI with melanoma, 2 BRAF mutations were 
found and these were different from the V600E mutation in 
Caucasians.[52] In the same study, 3 NRAS mutations were 
found on exon 1 in SCI, and this was different from what is 
observed in Caucasians in whom the mutation is on exon 2.[52]
CDKN2A encodes two growth inhibitors; p16 and alternative 
reading frame (ARF).[54] The p16-ARF is required by 
melanocytes for senescence and pigmentation. Melanoma 
genesis requires the melanocytes to overcome senescence, 
which is the normal progression of a benign naevus.[54] A study 
of 32 ALM revealed that there was no loss of p16 in ALM.[55] 
Hence, loss of p16 is not associated with ALM.
MC1R is involved in both pigment production and melanoma 
genesis.[51] The presence of multiple MCIR variants is 
associated with a risk of developing melanoma, especially at 
an early age because MCIR variants increase the penetrance 
of CDKN2A. In ALM, the subtype of melanoma most 
encountered in SCI, MCIR variants are low.[56]
In summary, gene mutation does occur in ALM, the most 
common subtype of melanoma in  SCI. The relevant gene 
mutations in ALM are CD1 and c-kit. The other genes found 
to be mutated in melanomas (BRAF, p16, MC1R) have a low 
occurrence in ALM and thus may not be relevant in SCI.
In conclusion, melanoma, although rare does occur in SCI. 
Most of the studies on cutaneous melanoma are from the 
Caucasian population with a resultant lack of details on the 
characteristics and peculiarities of cutaneous melanoma in 
SCI. The low incidence of melanoma in SCI is irrespective of 
geographical location and attributed to the protective effect of 
melanin. In SCI, the incidence of melanoma varies between 
males and females and also varies with age, with melanoma 
occurring more in males.
Sun exposure and trauma have not been found to be risk factors 
in SCI. Preexisting melanocytic nevi may be a risk factor 
for melanoma in SCI, especially ALM. The most common 
anatomic sites of melanoma occurrence in SCI is subungual 
and acral. Female SCI have melanomas only on their lower 
limbs, unlike their male counterparts who have melanomas not 
only on their lower limbs but also on other parts of their bodies.
There are some observed differences in melanoma between SCI 
and Caucasians. Melanoma is diagnosed almost a decade later 
in SCI compared to Caucasians. The risk factors for melanoma 
in SCI are not as well-known as in Caucasians. Melanoma is 
truncal in Caucasians and acral in SCI. Melanoma specific 
5-year survival is poor in SCI due to advanced, ulcerated 
lesions at presentation and low perception of the risk of 
melanoma both by physicians and patients. The genetics of 
melanoma has not been well studied in SCIs. For now, genetic 
mutations are inferred from studies carried out on Caucasians.
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